Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Warfarin for Recanalization in Acute DVT
NCT06145269Phase 1Unknown
- Sponsor
- Assiut University
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in deep vein thrombosis (DVT) (2 arms), sponsored by Assiut University. Primary endpoint: Recanalization rate of the thrombosed vein at 1 year. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NCT06145269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145269.